Overview

A Trial of HRS-4508 Combined With Other Antitumor Therapies in Subjects With Locally Advanced or Metastatic Non-small Cell Lung Cancer

Status:
NOT_YET_RECRUITING
Trial end date:
2028-12-01
Target enrollment:
Participant gender:
Summary
The study is being conducted to evaluate the efficacy, safety, and ORR of HRS-4508 combined with other antitumor therapies in subjects with locally advanced or metastatic non-small cell lung cancer; Evaluate the pharmacokinetic (PK) characteristics of HRS-4508 and other efficacy endpoints for the treatment of locally advanced or metastatic non-small cell lung cancer.
Phase:
PHASE2
Details
Lead Sponsor:
Jiangsu HengRui Medicine Co., Ltd.